At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antipsychotics; Small molecules
- Mechanism of Action Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 06 Dec 2000 Profile reviewed but no significant changes made
- 16 Jun 1998 No-Development-Reported for Psychotic disorders in USA (Unknown route)
- 04 Mar 1996 New profile